| Aspirin formulation for cardiovascular health -> Monitor Keywords |
|
|
 
Aspirin formulation for cardiovascular healthRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Plant Material Or Plant Extract Of Undetermined Constitution As Active Ingredient (e.g., Herbal Remedy, Herbal Extract, Powder, Oil, Etc.), Containing Or Obtained From Allium (e.g., Onion, Garlic, Ramp, Chive, Scallion, Etc.)Aspirin formulation for cardiovascular health description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20070166412, Aspirin formulation for cardiovascular health. Brief Patent Description - Full Patent Description - Patent Application Claims
INCORPORATION BY REFERENCE [0001] This application is a continuation of U.S patent application Ser. No. 11/323,091 filed Dec. 30, 2005. Reference is also made to U.S patent application Ser. No. 11/323,093 filed Dec. 30, 2005. [0002] The foregoing applications, and all documents cited therein or during their prosecution ("appln cited documents") and all documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. Reference is also made to copending application Serial No. To Be Assigned (attorney docket no. 870052-2002.1C) filed Mar. 19, 2007. FIELD OF THE INVENTION [0003] The invention relates generally to an aspirin formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for maintaining cardiovascular health. BACKGROUND OF THE INVENTION [0004] Cardiovascular disease is the leading cause of death in the United States and many other countries. Nutritional factors are widely recognized as playing a role in preventing, delaying the onset of and/or slowing the progression of arteriosclerosis and coronary heart disease. [0005] Most risk markers for cardiovascular disease have a pro-inflammatory component, which stimulates the release of a number of active molecules such as inflammatory mediators, reactive oxygen species, nitric oxide, and peroxynitrite from endothelial, vascular smooth muscle, and immune cells in response to injury (reviewed by Osiecki, Altern Med Rev. March 2004;9(1):32-53). Nutrients such as arginine, antioxidants (vitamins C and E, lipoic acid, glutathione), and enzyme cofactors (vitamins B2 and B3, folate, and tetrahydrobiopterin) help to elevate nitric oxide levels and may play an important role in the management of cardiovascular disease. Other dietary components such as DHA/EPA from fish oil, tocotrienols, vitamins B6 and B12, and quercetin contribute further to mitigating the inflammatory process. [0006] Aspirin has a role in the prevention of cardiovascular and cerebrovascular disease, Alzheimer's dementia and several cancers. Encouraging all 50 year olds to take low-dose aspirin doubles their chances of living a healthy life into their nineties. The widespread use of aspirin, however, is limited as many older subjects are currently unable to take aspirin because of gastrointestinal side-effects. A review by Newton et al. (Aliment Pharmacol Ther. Jan. 1, 2004; 19(1):39-45) explores why gastrointestinal events occur with aspirin use and how a net benefit from prophylactic aspirin might be achieved in older subjects. It is suggested that, by understanding the age-related changes in upper gastrointestinal physiology and the mechanisms by which aspirin leads to the risk reductions associated with its use, it may be possible to direct interventions to improve tolerability in older subjects. [0007] Aspirin (acetylsalicylic acid), the most widely used antiplatelet drug, is clinically effective for the prevention of vascular ischaemic events (reviewed by Mahe et al. Drugs Aging. 2003;20(13):999-1010). Very few primary or secondary prevention trials address the benefit-risk ratio of aspirin in the elderly. In secondary prevention, it is generally accepted that the beneficial effect of aspirin in the general patient population, demonstrated by randomised controlled trials, can be extrapolated to the elderly. Elderly patients are at relatively high risk for the development of vascular disease and might also be expected to derive substantial benefit from regular aspirin administration. Retrospective studies in the elderly found that the benefit provided by aspirin in older patients was similar or increased compared with younger individuals. In primary prevention, the potential benefit of antiplatelet agents must be balanced against the risk of bleeding, which is higher in older patients. [0008] The gastro-intestinal (GI) toxicity associated with high dose aspirin has been fully demonstrated, but remains poorly elucidated at low doses i.e., less than 500 mg/day (reviewed by Sibilia et al., Presse Med. Nov. 22, 2004;32(37 Pt 2):S17-28). Such toxicity is relatively difficult to study because lesional and/or bleeding GI complications are not always well described in studies. The GI risk exists, starting with the lowest doses and appears to be dose-dependent. The lesional complications consist mainly of erosive lesions, most often gastric, and rarely true ulcers. Cases of bleeding appear more frequent, but generally are minor. [0009] Low-dose aspirin is an important therapeutic option in the prevention of cardiovascular disease, including myocardial infarction and ischemic stroke, especially in light of its unique cost-effectiveness and widespread availability (reviewed by Gorelick & Weisman, Stroke. August 2005; 36(8):1801-7. Epub Jul. 14, 2005). In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage. [0010] Attempts have been made to design multivitamin supplements specifically for heart health. Examples include U.S. Pat. No. 5,770,215, which relates to a multivitamin composition containing various vitamins, minerals, and acetylsalicylic acid, U.S. Pat. No. 5,948,443, which pertains to an acetylsalicylic acid and micronutrient supplement, U.S. Pat. No. 6,914,073 which relates to a composition containing a high level of Vitamin E in encapsulated form, U.S. Pat. No. 6,953,593, which pertains to a microencapsulation process or a sustained release formulation for oral delivery with a microencapsulated core material, International Patent Publication WO 98/41195, which encompasses a nutritional supplement containing at least one flavonoid and folic acid or folate, International Patent Publication WO 03/030818 and related U.S. patent application Ser. Nos. 10/264,205 and 10/864,149, which pertain to active agent compositions using liposome beads and International Patent Publication No. WO 03/020260 and related U.S. patent application Ser. Nos. 11/141,085 and 10/234,002, which pertain to compositions comprising at least one arginine compound or conjugate thereof and at least one member selected from the group consisting of high molecular weight aliphatic alcohol and methyl donor cofactor and conjugates thereof and methods of using the same. [0011] There is a need for formulations with a low dose of aspirin with supplements to limit gastro-intestinal toxicity to prevent cardiovascular disease. [0012] Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention. SUMMARY OF THE INVENTION [0013] The invention is based, in part, on the Applicants' discovery that a combination of low dose aspirin and dietary supplements that may control cholesterol or blood pressure levels. [0014] The invention is based upon a formulation which may comprise, consist essentially of or consist of aspirin, vitamin B6, vitamin B12, folic acid, arginine and garlic. Advantageously, the aspirin is a low dose of aspirin. The folic acid may also encompass folate. In another advantageous embodiment, the arginine may be L-arginine, the garlic may be a garlic extract, advantageously an aged garlic extract or an aged garlic extract powder. In a particularly advantageous embodiment, the formulation may comprise, consist essentially of or consist of a low dose of aspirin, vitamin B6, vitamin B12, folic acid or folate, L-arginine, aged garlic extract powder, or any combination thereof. [0015] The invention also provides for a caplet or tablet which may comprise a formulation which may comprise, consist essentially of or consist of aspirin, vitamin B6, vitamin B12, folic acid, arginine and garlic. Advantageously, the aspirin is a low dose of aspirin. The folic acid may also encompass folate. In another advantageous embodiment, the arginine may be L-arginine, the garlic may be a garlic extract, advantageously an aged garlic extract or an aged garlic extract powder. In a particularly advantageous embodiment, the caplet or tablet comprises a formulation may comprise, consist essentially of or consist of a low dose of aspirin, vitamin B6, vitamin B12, folic acid or folate, L-arginine, aged garlic extract powder, or any combination thereof. [0016] Advantageously, dosage per caplet or tablet of aspirin is 81 mg, vitamin B6 is 25 mg, vitamin B12 is 200 mcg, folic acid or folate is 600 mcg, arginine, advantageously L-arginine, is 200 mg and garlic, advantageously a garlic extract, an aged garlic extract or an aged garlic extract powder, is 500 mg. The caplet or tablet of may further comprise cellulose, silica and magnesium stearate. In another embodiment, the caplet or tablet may further comprise calcium carbonate, camauba wax, colloidal silicon dioxide, crospovidone, hypromellulose, lactose, magnesium stearate, maltodextrin, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, stearic acid, titanium dioxide, tracetin, zinc stearate or any combination thereof. Preferably, the caplet or tablet does not contain gluten, preservatives, sugar, sodium, milk, yeast, artificial colors, artificial flavors or any combination thereof. [0017] Advantageously, the caplet or tablet may be enteric coated. [0018] The present invention also provides for method of maintaining healthy blood pressure and cholesterol levels which may comprise administering any of the above-described caplets or tablets which may comprise any one of the above-described formulations to a patient in need of maintenance of healthy blood pressure and cholesterol levels. In an advantageous embodiment, the caplet or tablet may be administered once per day. [0019] It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of" and "consists essentially of" have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention. [0020] These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description. Continue reading about Aspirin formulation for cardiovascular health... Full patent description for Aspirin formulation for cardiovascular health Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Aspirin formulation for cardiovascular health patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Aspirin formulation for cardiovascular health or other areas of interest. ### Previous Patent Application: Nutritional supplement containing long-chain polyunsaturated fatty acids Next Patent Application: Cholestrol-reducing agent containing an n-3 fatty acid Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Aspirin formulation for cardiovascular health patent info. IP-related news and info Results in 0.14568 seconds Other interesting Feshpatents.com categories: Electronics: Semiconductor , Audio , Illumination , Connectors , Crypto , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
